The Race to the $1,000 Genome – Motley Fool
But what happens when progress is so rapid that the law gets left behind? For biotech investors (not to mention patients), the answer is more complex -- and potentially transformative -- than it may seem at first glance. The exponential trend of ...
Subscribe to LegalLaw247.Com Newsletter